Clinical Communications

Real-world attitudes among allergists/immunologists regarding oral immunotherapy and preferred terminology

Aimmune Therapeutics, Inc. provided financial support for the conduct of the research and preparation of the article. K.R. (former employee) and E.Z., an employee of Aimmune Therapeutics, Inc. collaborated with the remaining authors on the study design, the collection, analysis, and interpretation of data, the writing of the report, and in the decision to submit the article for publication.

Conflicts of interest: B. E. Chipps reports consulting and speakers' bureau fees from AstraZeneca, Boehringer Ingelheim, Circassia, Genentech, Novartis, and Teva, and consulting fees from Regeneron and Sanofi. C. E. Ciaccio has received consulting and advisory board fees from Aimmune Therapeutics. K. Rosén was formerly an employee of Aimmune Therapeutics. T. Haselkorn is a consultant for Aimmune Therapeutics. E. Zigmont is an employee of and owns stock in Aimmune Therapeutics. T. B. Casale is a consultant and has received research funding from Aimmune Therapeutics.

K. Rosén is no longer affiliated with Aimmune Therapeutics, but she was at the time of the writing of this article.